Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 2 NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 18 Pancreatic Neoplasms 17 Lung Neoplasms 14 Carcinoma, Non-Small-Cell Lung 14 Biliary Tract Neoplasms 10 Urethral Neoplasms 9 Lymphoma 8 Uterine Cervical Neoplasms 6 Ovarian Neoplasms 6 Gallbladder Neoplasms 6 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, Large-Cell, Anaplastic 4 Hodgkin Disease 4 Carcinoma, Ovarian Epithelial 4 Breast Neoplasms 4 Sarcoma 3 Kidney Neoplasms 3 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 3 Bile Duct Neoplasms 3 Salivary Gland Neoplasms 2 Recurrent Uterine Corpus Sarcoma 2 Recurrence 2 Non-Muscle Invasive Bladder Neoplasms 2 Neoplasm Metastasis 2 Mesothelioma, Malignant 2 Lymphoma, Non-Hodgkin 2 Immunoblastic Lymphadenopathy 2 Fallopian Tube Neoplasms 2 Adenocarcinoma of Lung 2

Interventions

Trastuzumab 1 IFL protocol 1 Gemcitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Advanced Cancer × Gemcitabine × Clear all

NCT05605509 2026-02-06

RP-6306 in Patients With Advanced Cancer

Canadian Cancer Trials Group

Phase 2 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡